Amgen (NASDAQ:AMGN) today announced that the U.S.FDA has approved the supplemental New Drug Application to add the positive overall survival data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (carfilzomib).
Contributed Author:
Amgen
Topics:
More From BioPortfolio on "FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS® Label"